The Role of Histamine in Muscle Protein Synthesis Following Resistance Training

The Role of Histamine in Muscle Protein Synthesis Following Chronic Resistance Training

Blocking histamine H1/H2 receptors blunts chronic endurance training adaptations. The current study addresses the following research question: "What is the influence of histamine H1 signaling on training adaptations following ten weeks of resistance training in human skeletal muscle." Results from this study will yield more insights into the molecular mechanisms of adaptations to exercise training.

Study Overview

• Status: Recruiting
• Conditions: Histamine
• Intervention / Treatment: Drug: Placebo; Behavioral: Resistance training; Drug: H1 blockade: Telfast: 180mg Fexofenadine

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Wim Derave, Professor; Phone Number: +32 92646326; Email: wim.derave@ugent.be

Study Locations

• Belgium
  • Oost-Vlaanderen
    • Ghent, Oost-Vlaanderen, Belgium, 9000
      • Recruiting
      • Department of movement and sports sciences, Ghent University, Belgium
      • Contact: Wim Derave, Professor; Phone Number: +32 92646326; Email: wim.derave@ugent.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male
• 18-45 years
• Not to medium physically active

Exclusion Criteria:

• Smoking
• Chronic disease
• High blood pressure
• Supplement or medication intake
• Seasonal allergies
• Vegetarian / vegan
• Resistance trained

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: 1: Placebo; Lactose	Drug: Placebo; Oral placebo; Behavioral: Resistance training; Resistance training: lower body exercise
Experimental: H1 blockade: Telfast (180mg Fexofenadine); H1: Telfast (180mg Fexofenadine)	Behavioral: Resistance training; Resistance training: lower body exercise; Drug: H1 blockade: Telfast: 180mg Fexofenadine; H1 blockade: oral blockade with 180mg Fexofenadine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle volume	Change in muscle volume	Before and after the 10 weeks of resistance training
Maximal dynamic strength of leg press, bench press, bicep curl and leg curl	Change in maximal dynamic strength of leg press, bench press, bicep curl and leg curl	Before and after the 10 weeks of resistance training
Muscle fiber hypertrophy in muscle biopsies	Change in muscle fiber hypertrophy in muscle biopsies	Before and after the 10 weeks of resistance training
Vascular function measured with a single passive leg movement (sPLM: change in femoral blood flow measured with Doppler ultrasound before and after one passive flexion/extension of the leg)	Change in vascular function with a single passive leg movement (sPLM: change in femoral blood flow measured with Doppler ultrasound before and after one passive flexion/extension of the leg)	Before and after the 10 weeks of resistance training
Matsuda index, to estimate whole body glucose metabolism, will be calculated using an oral glucose tolerance test (OGTT: concentration of glucose and insulin in the blood will be measured before and after drinking 75g glucose)	Change in Matsuda index, to estimate whole body glucose metabolism, will be calculated using an oral glucose tolerance test (OGTT: concentration of glucose and insulin in the blood will be measured before and after drinking 75g glucose)	Before and after the 10 weeks of resistance training

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood pressure (systolic and diastolic)	Chance in Blood pressure (systolic and diastolic)	Before and after the 10 weeks of resistance training
Resting heart rate	Chance in Resting heart rate	Before and after the 10 weeks of resistance training

Collaborators and Investigators

• Sponsor: University Ghent
• Collaborators: Research Foundation Flanders
• Investigators: Principal Investigator: Wim Derave, Professor, University Ghent

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2023
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: December 20, 2022
• First Submitted That Met QC Criteria: November 29, 2023
• First Posted (Actual): November 30, 2023

Study Record Updates

• Last Update Posted (Estimated): December 13, 2023
• Last Update Submitted That Met QC Criteria: December 6, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Allergic Agents; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Histamine H1 Antagonists, Non-Sedating; Fexofenadine
• Other Study ID Numbers: MPSH - ONZ-2023-0027

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No